Mahamaya Lifesciences IPO Subscription Day 3: Check Online

Check Expert’s Verdicts on Mahamaya Lifesciences IPO. 

Here is the Mahamaya Lifesciences IPO launched on 11th November 2025. Bidding for the issue will close on 13th November 2025. The primary aim of the Mahamaya Lifesciences IPO is to raise ₹70.44 crores from the market. Additionally, the Mahamaya Lifesciences IPO has received an impressive level of subscription, indicating that the shares will likely be listed at a premium. Scroll down to check the Mahamaya Lifesciences IPO subscription and details. 

Mahamaya Lifesciences IPO Details 

The price band for the Mahamaya Lifesciences IPO has been prescribed at ₹108 to ₹114 per share, with a total of 61,78,800 shares issued. Let’s segregate the share quota fixed for different categories of investors. 

Mahamaya Lifesciences IPO Subscription Status

As of now, the Mahamaya Lifesciences IPO has been subscribed to 0.16 times. Of these, 0.12 times are subscribed by retail investors, 0.01 times by non-institutional investors, and 0.35 times by QII (Qualified Institutional Investors).  

The healthy subscription status indicates that investors are expecting higher returns at the time of the Mahamaya Lifesciences IPO, scheduled for listing on 18th November 2025. Mahamaya Lifesciences’ IPO also has a positive outlook, with the fresh issue of 56.00.000 shares to raise around Rs 70.44 crores.

Mahamaya Lifesciences IPO GMP Today

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Mahamaya Lifesciences IPO GMP for 13th November 2025. 

The grey market premium for this IPO is 0.00% or Rs 0 per share. It indicates that the estimated listing price per share is Rs 114. Numerous factors played a pivotal role in the jump in Mahamaya Lifesciences IPO GMP. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs. 

About Mahamaya Lifesciences Ltd.

Mahamaya Lifesciences Limited was established in 2007 and is engaged in the manufacturing, registration, and export of high-quality crop protection products and bioproducts for crop & soil health management, aiming to enhance productivity in the farming community. The company specialises in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs). The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).

• Experienced management team consisting of experts.
• Capability to introduce vital products for Indian Agriculture.
• Development of export opportunities for products.
• Ability to develop brands.
• Cordial relationships with suppliers of raw materials.
• Core values focused on achieving sustainability through innovative approaches.

Mahamaya Lifesciences Limited Financials

The company’s financial analysis is essential before applying for Mahamaya Lifesciences Limited’s IPO. Look at the table to learn about Mahamaya Lifesciences Limited’s financials. 

Explanation

Mahamaya Lifesciences Limited’s revenue increased by 64% from ₹162.83 crore in March 2024 to ₹267.17 crore in March 2025. Moreover, the company’s PAT increased by 148% from ₹5.22 crores to ₹12.94 crores. Investors can analyse other relevant factors and make a decision accordingly.

Technical Indicators

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technical aspects of the Mahamaya Lifesciences IPO.

Mahamaya Lifesciences IPO Listing Expectations

Mahamaya Lifesciences IPO Highlights: IPO allotment is still pending, as the bid closes today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A 0.00% jump in the GMP of Mahamaya Lifesciences’s IPO suggests that the estimated listing price per share will be around Rs 0.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Mahamaya Lifesciences IPO Dates

Note: IPO GMP is volatile, driven by market sentiment. Hence, one should conduct their research before investing in it.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Mahamaya Lifesciences IPO IPO GMP: Day 2 IPO Live Updates